Key Highlights

  • ICON Public Limited Company (NASDAQ:ICLR) reports third-quarter results after the close on Tuesday, October 27, 2026, with consensus adjusted earnings of USD 2.63 per share, according to consensus estimates.
  • Second-quarter adjusted earnings were USD 2.56 per share, down from USD 3.52 a year earlier, on revenue of USD 2,063.5 million, which rose 1.2%. Gross bookings reached USD 3,681 million.
  • The company reaffirmed 2026 guidance of revenue between USD 7,850 million and USD 8,150 million and adjusted earnings between USD 10.00 and USD 11.00 per share.
  • Backlog stood at USD 23.4 billion at June 30, 2026, up 3.0% from the first quarter, with a net book-to-bill ratio of 1.51.

The Setup and the Last Quarter

ICON Public Limited Company (NASDAQ:ICLR) is an Ireland-based contract research organisation that runs clinical trials for drug and device developers, and it reports third-quarter results after the close on Tuesday, October 27, 2026. Consensus adjusted earnings are USD 2.63 per share. In its release of Wednesday, July 29, 2026, the company reported second-quarter revenue of USD 2,063.5 million, up 1.2% and 0.4% in constant currency, adjusted earnings of USD 2.56 per share against USD 3.52 a year earlier, and adjusted EBITDA of USD 327.2 million, or 15.9% of revenue. GAAP diluted earnings were USD 0.94 per share. The fall in earnings shows that margin pressure persisted.

Why Bookings and Cancellations Matter

A contract research organisation turns bookings into revenue over several years, so the backlog is the best guide to future growth. ICON (NASDAQ:ICLR) reported second-quarter gross bookings of USD 3,681 million, cancellations of USD 562 million and net bookings of USD 3,120 million, which produced a net book-to-bill ratio of 1.51, meaning new orders were 1.51 times revenue. A ratio above 1.0 indicates a growing backlog, which reached USD 23.4 billion. The challenge is conversion: revenue growth of 1.2% is slow relative to that backlog, and adjusted earnings fell sharply. Management guided the full year to USD 10.00 to USD 11.00 per share, so a USD 2.63 consensus must be read against that wide range.

Risks and What to Watch

The bull case for ICON (NASDAQ:ICLR) is a book-to-bill ratio above 1.2, cancellations that stay below the second-quarter level of USD 562 million and a margin that stabilises, which would indicate that biotech funding is feeding new trials and would probably help the shares. The bear case is adjusted earnings below USD 2.50, a lower end of the revenue range of USD 7,850 million to USD 8,150 million, or a rise in cancellations that erodes the USD 23.4 billion backlog. Customers' budgets and project delays are the principal risks, and the Federal Reserve rate rise of Wednesday, September 16, 2026 increases funding costs for smaller drug developers. Investors should watch the Federal Reserve decision on Wednesday, October 28, 2026.

Where Things Stand

The answer is that ICON (NASDAQ:ICLR) can reach a USD 2.63 consensus, which sits above the USD 2.56 of the second quarter, if revenue conversion improves, but bookings quality and the full-year range will decide the reaction. A narrowing towards the lower half of USD 10.00 to USD 11.00 would be read cautiously. The next catalysts are the results after the close on Tuesday, October 27, 2026 and the Federal Reserve decision on Wednesday, October 28, 2026. Consensus figures and company guidance are estimates, not guarantees, and this is not investment advice.